Capital Fund Management S.A. Sells 16,172 Shares of United Therapeutics Corporation $UTHR

Key Points

• Capital Fund Management S.A. has reduced its stake in United Therapeutics Corporation by 40.2%, selling 16,172 shares and now holds approximately 0.05% of the company worth $7,417,000.
• Several institutional investors have made adjustments to their positions, with 94.08% of the company's stock now owned by institutional investors.
• United Therapeutics' latest quarterly earnings report showed an EPS of $6.41, missing estimates, while revenue increased 11.7% year-over-year.

Capital Fund Management S.A. decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 40.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,061 shares of the biotechnology company's stock after selling 16,172 shares during the quarter. Capital Fund Management S.A. owned approximately 0.05% of United Therapeutics worth $7,417,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Hohimer Wealth Management LLC boosted its position in United Therapeutics by 0.3% during the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after acquiring an additional 37 shares during the last quarter. Applied Finance Capital Management LLC boosted its position in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after purchasing an additional 40 shares in the last quarter. Headlands Technologies LLC grew its stake in shares of United Therapeutics by 1.5% in the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock valued at $828,000 after buying an additional 40 shares during the period. Dunhill Financial LLC grew its stake in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares during the period. Finally, Callan Family Office LLC grew its stake in shares of United Therapeutics by 5.4% in the 1st quarter. Callan Family Office LLC now owns 968 shares of the biotechnology company's stock valued at $298,000 after buying an additional 50 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 645 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,681 shares of company stock valued at $24,618,359. Company insiders own 10.30% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on UTHR shares. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Bank of America reduced their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. JPMorgan Chase & Co. reduced their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Finally, HC Wainwright set a $400.00 target price on United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $382.00.

United Therapeutics Stock Performance

Shares of UTHR opened at $310.66 on Friday. The stock has a 50 day moving average price of $296.44 and a two-hundred day moving average price of $307.95. The firm has a market capitalization of $14.01 billion, a P/E ratio of 12.13, a P/E/G ratio of 4.64 and a beta of 0.57. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm posted $5.85 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.